Theravance Biopharma, Inc. (TBPH) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been given an average rating of “Hold” by the twelve analysts that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $42.00.
A number of brokerages recently commented on TBPH. BidaskClub upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a report on Saturday. Cantor Fitzgerald began coverage on shares of Theravance Biopharma in a report on Friday, June 16th. They set an “overweight” rating and a $55.00 price objective on the stock. ValuEngine upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Leerink Swann set a $47.00 price objective on shares of Theravance Biopharma and gave the stock a “buy” rating in a report on Wednesday, May 10th. Finally, Needham & Company LLC raised their price objective on shares of Theravance Biopharma from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, May 11th.
Theravance Biopharma (NASDAQ TBPH) opened at 41.59 on Tuesday. The stock’s 50 day moving average is $38.07 and its 200 day moving average is $34.32. The stock’s market capitalization is $2.22 billion. Theravance Biopharma has a 12-month low of $21.30 and a 12-month high of $43.44.
Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.14) by $0.13. Theravance Biopharma had a negative return on equity of 67.69% and a negative net margin of 641.67%. The company had revenue of $3.09 million for the quarter, compared to analyst estimates of $5.07 million. Analysts forecast that Theravance Biopharma will post ($4.64) EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. acquired a new position in Theravance Biopharma during the fourth quarter worth $464,000. State Street Corp increased its position in Theravance Biopharma by 18.3% in the fourth quarter. State Street Corp now owns 851,024 shares of the biopharmaceutical company’s stock worth $27,136,000 after buying an additional 131,646 shares during the period. Franklin Resources Inc. acquired a new position in Theravance Biopharma during the fourth quarter worth $12,095,000. Two Sigma Investments LP increased its position in Theravance Biopharma by 153.3% in the fourth quarter. Two Sigma Investments LP now owns 26,931 shares of the biopharmaceutical company’s stock worth $859,000 after buying an additional 16,299 shares during the period. Finally, Norges Bank acquired a new position in Theravance Biopharma during the fourth quarter worth $27,631,000. 84.30% of the stock is owned by institutional investors and hedge funds.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.